Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG

Autor: Dale L. Bixby, Gianni B. Scappaticci, Bernard L. Marini, Ashley Crouch, Moshe Talpaz, Anthony J. Perissinotti, Victoria R Nachar, James R. Uebel, Vera Vulaj
Rok vydání: 2017
Předmět:
Aging
Michigan
Palliative care
Cohort Studies
Tertiary Care Centers
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Granulocyte Colony-Stimulating Factor
Medicine
Clofarabine
Hospital Costs
Aged
80 and over
education.field_of_study
Adenine Nucleotides
Incidence
Cytarabine
Induction Chemotherapy
Hematology
General Medicine
Middle Aged
Combined Modality Therapy
Fludarabine
Leukemia
Myeloid
Acute
030220 oncology & carcinogenesis
Costs and Cost Analysis
Chemical and Drug Induced Liver Injury
Vidarabine
medicine.drug
Antimetabolites
Antineoplastic
medicine.medical_specialty
Neutropenia
Population
03 medical and health sciences
Cost Savings
Internal medicine
Humans
Propensity Score
education
Aged
Retrospective Studies
business.industry
Length of Stay
medicine.disease
Survival Analysis
Regimen
Case-Control Studies
FLAG (chemotherapy)
Arabinonucleosides
business
030215 immunology
Zdroj: Annals of Hematology. 97:573-584
ISSN: 1432-0584
0939-5555
DOI: 10.1007/s00277-017-3217-1
Popis: The 5-year overall survival (OS) in patients ≥ 60 years old with acute myeloid leukemia (AML) remains
Databáze: OpenAIRE
Externí odkaz: